CAC
PTLA

Cowen and Company’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Cowen and Company’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26,081
Closed -$186K – 550
2020
Q1 		$186K Buy
+26,081
New +$325K 0.04% 201

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Cowen and Company's PTLA Position: Q2 2020 in Review

Cowen and Company sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 26,081 shares — an estimated $186K sold.

Cowen and Company first reported a position in PTLA in Q1 2020 and held it in 1 quarter. The position peaked at $186K in Q1 2020. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Cowen and Company reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Cowen and Company sold 26,081 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $186K.
  • Cowen and Company first reported a position in Portola Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Cowen and Company's Portola Pharmaceuticals, Inc. position peaked at $186K in Q1 2020.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Cowen and Company's 13F filing for Q2 2020, filed 13 Aug 2020.